title: Glycogen Storage Disease Because of a PRKAG2 Mutation Causing Severe Biventricular Hypertrophy and High-Grade Atrio-Ventricular Block.
authors: From the Division of Cardiology, Department of Medicine (H.Y., I.D.P., M.G., G.Y.O.), Mazankowski Alberta Heart Institute (H.Y., I.D.P., M.G., G.Y.O.), and Department of Laboratory Medicine and Pathology (C.S.), University of Alberta, Edmonton, Canada.
authors: Haran
authors: H
authors: Yogasundaram
authors: From the Division of Cardiology, Department of Medicine (H.Y., I.D.P., M.G., G.Y.O.), Mazankowski Alberta Heart Institute (H.Y., I.D.P., M.G., G.Y.O.), and Department of Laboratory Medicine and Pathology (C.S.), University of Alberta, Edmonton, Canada.
authors: Ian D
authors: ID
authors: Paterson
authors: From the Division of Cardiology, Department of Medicine (H.Y., I.D.P., M.G., G.Y.O.), Mazankowski Alberta Heart Institute (H.Y., I.D.P., M.G., G.Y.O.), and Department of Laboratory Medicine and Pathology (C.S.), University of Alberta, Edmonton, Canada.
authors: Michelle
authors: M
authors: Graham
authors: From the Division of Cardiology, Department of Medicine (H.Y., I.D.P., M.G., G.Y.O.), Mazankowski Alberta Heart Institute (H.Y., I.D.P., M.G., G.Y.O.), and Department of Laboratory Medicine and Pathology (C.S.), University of Alberta, Edmonton, Canada.
authors: Consolato
authors: C
authors: Sergi
authors: From the Division of Cardiology, Department of Medicine (H.Y., I.D.P., M.G., G.Y.O.), Mazankowski Alberta Heart Institute (H.Y., I.D.P., M.G., G.Y.O.), and Department of Laboratory Medicine and Pathology (C.S.), University of Alberta, Edmonton, Canada. gavin.oudit@ualberta.ca.
authors: Gavin Y
authors: GY
authors: Oudit
mesh_terms: D055372:AMP-Activated Protein Kinases / Q000235:genetics*; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D054537:Atrioventricular Block / Q000000981:diagnostic imaging / Q000235:genetics* / Q000503:physiopathology / Q000628:therapy; D001706:Biopsy; D002304:Cardiac Pacing, Artificial; D004252:DNA Mutational Analysis; D017147:Defibrillators, Implantable; D015150:Echocardiography, Doppler; D004554:Electric Countershock / Q000295:instrumentation; D004562:Electrocardiography; D020022:Genetic Predisposition to Disease; D006008:Glycogen Storage Disease / Q000150:complications / Q000175:diagnosis / Q000201:enzymology / Q000235:genetics*; D040941:Heredity; D006801:Humans; D017379:Hypertrophy, Left Ventricular / Q000000981:diagnostic imaging / Q000235:genetics* / Q000503:physiopathology / Q000628:therapy; D017380:Hypertrophy, Right Ventricular / Q000000981:diagnostic imaging / Q000235:genetics* / Q000503:physiopathology / Q000628:therapy; D008279:Magnetic Resonance Imaging; D008297:Male; D020125:Mutation, Missense; D010375:Pedigree; D010641:Phenotype; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; C526223:PRKAG2 protein, human; D055372:AMP-Activated Protein Kinases
keywords: cardiomyopathies; genetics; heart diseases; hypertrophy; microscopy, electron; syncope